Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 tablets in macrophage activation syndrome and secondary hemophagocytic syndrome (single-arm, multicenter Ib/II study)
CTR20244567Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rovadicitinib in macrophage activation syndrome (MAS), haemophagocytic lymphohistiocytosis (HLH), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2024; status: active.
02
Drugs
rovadicitinib
03
Conditions
macrophage activation syndrome (MAS)haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on CTR20244567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244567.